Marc-Oliver Grimm talks through the results of the tailored nivolumab plus boost ipilimumab approach used in the TITAN-RCC study (3:38).
30-09-2019 | Renal cell carcinoma | Video | Article
Marc-Oliver Grimm talks through the results of the tailored nivolumab plus boost ipilimumab approach used in the TITAN-RCC study (3:38).